Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04682431
Other study ID # PY159-2-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 10, 2020
Est. completion date August 31, 2023

Study information

Verified date March 2024
Source Ikena Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).


Description:

Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard 3+3 design Part B: Dose expansion of one or more dose levels of PY159 administered alone and in combination with pembrolizumab for predefined tumor histology


Recruitment information / eligibility

Status Terminated
Enrollment 127
Est. completion date August 31, 2023
Est. primary completion date August 25, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility KEY ELIGIBILITY CRITERIA Inclusion Criteria - Adults =18 years of age at the time of study consent - Subjects with any of the following eligible solid tumor diagnoses as confirmed by cytology or histology. Escalation Cohorts (Part A): Subjects with advanced solid tumors from pre-specified tumor types: - head and neck [squamous cell carcinoma, salivary gland, thyroid], - gynecologic [including ovarian, fallopian, primary peritoneal, endometrial, cervical, uterine, vaginal, vulvar], - pancreatic [adenocarcinoma], - lung [adenocarcinoma and squamous cell carcinoma] who are recurrent or refractory to platinum-based chemotherapy in addition to prior treatment with CPI Programmed Cell Death-1 (PD-1)/Programmed Cell Death-Ligand 1 (PD-L1) or who give informed consent to forego such therapy, - gastric and esophagogastric junction adenocarcinomas [MSI low and CPI refractory MSI high], - breast [TNBC and HR+, HER2-] with metastatic disease that is relapsed or refractory to at least one line of post adjuvant therapy (including a CPI-either alone or in combination, if approved for that indication, and not eligible for other targeted therapies specific for their tumor type). - Subjects must provide an original, diagnostic tumor sample to determine TREM1 expression (sites have verified source prior to screening and availability of archival tissue during screening). For Part A subjects without an archival tissue sample will only be eligible if they choose and consent to provide a CNB of a primary or metastatic lesion. - Subjects must have documented radiographic disease progression that include prior treatment with a CPI (alone or in combination), if approved for that indication. - There is no limit to the number of prior treatments - Measurable disease by RECIST 1.1. - All acute toxic effects of any prior antitumor therapy, including immunotherapy, have resolved to Grade < 2 before the start of study drug dosing (except for alopecia or peripheral neuropathy which may be Grade <2 or medication controlled thyroid replacement therapy). - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2. Exclusion Criteria - Subject is a candidate for approved molecularly targeted therapy (e.g., drugs targeting EGFR,VEGF, ALK, ROS-1, NTRK, MET, RET, and BRAF V600E, HER2). Applies to enrolled subjects on both Part A and Part B of the study. - History of autoimmune disorder requiring ongoing or intermittent disease-modifying therapy excluding thyroid disease well controlled on replacement therapy. - Untreated and/or uncontrolled brain metastases Stable treated or asymptomatic brain metastases (for at least 1 month prior to enrollment may be enrolled. Subjects with stable treated or asymptomatic brain metastases receiving glucocorticoids must be on a stable dose [= 2 mg/day of dexamethasone or an equivalent glucocorticoid] for a minimum of 1month prior to enrollment.) - Uncontrolled intercurrent illness including, but not limited to, active SARS-CoV-2 infection, active or chronic bleeding event within 28 days prior to first dose of study drug or psychiatric illness/social situation that would limit compliance with study requirements as judged by treating physician. - Decompensated liver disease as evidenced by hepatic encephalopathy or coagulopathy. - Active angina or Class III or IV Congestive Heart Failure (CHF) (NYHA CHF Functional Classification System) or clinically significant cardiac disease within 12 months of first dose. of study drug, including MI, unstable angina, Grade 2 or greater peripheral vascular disease, uncontrolled HTN, or arrhythmias not controlled by medication. - Any anti-cancer therapy, including small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy (with the exception of bone-modifying agents as supportive care), radiotherapy or any other agents to treat cancer within 14-21 days (dependent upon the agent and drug half-life) of first dose of study drug. Subjects with a prior history of prostate cancer on LHRH agonist are eligible provided they have no evidence of metastatic disease. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Drug:
PY159 Single agent dose level 1
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 2
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 3
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 4
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 5
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 6
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159 Single agent dose level 7
Dose of PY159 as a single agent given in a standard 3+3 design.
PY159/Pembrolizumab Combination dose level 1
Dose of PY159 and given in combination with pembrolizumab
PY159/Pembrolizumab Combination dose level 2
Dose of PY159 and given in combination with pembrolizumab
PY159/Pembrolizumab Combination dose level 3
Dose of PY159 and given in combination with pembrolizumab
PY159/Pembrolizumab Combination dose level 4
Dose of PY159 and given in combination with pembrolizumab
PY159 Single agent dose expansion cohort
Dose of PY159 as a single agent given for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 1
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 2
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 3
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 4
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 5
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
PY159/Pembrolizumab Combination dose expansion cohort 6
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology

Locations

Country Name City State
United States University of Colorado Aurora Colorado
United States Massachusetts General Hospital Boston Massachusetts
United States Case Western Reserve University Cleveland Ohio
United States Mary Crowley Cancer Center Dallas Texas
United States Karmanos Cancer Institute Detroit Michigan
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Indiana University Indianapolis Indiana
United States USC Norris Cancer Center Los Angeles California
United States Rutgers Cancer Institute of New Jersey New Brunswick New Jersey
United States Smilow Cancer Hospital at Yale New Haven New Haven Connecticut
United States The University of Oklahoma Norman Oklahoma
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States Start South Texas Accelerated Research Therapeutic San Antonio Texas
United States UCSF Mount Zion Cancer Center San Francisco California
United States UCLA Parkside Cancer Center Santa Monica California
United States Florida Cancer Specialists - Sarasota - SCRI Sarasota Florida

Sponsors (1)

Lead Sponsor Collaborator
Ikena Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Progress free survival (PFS) PFS will be measure from entry onto the study until disease progression or death from any cause. PFS will be assessed using KAPLAN-MEIER methods. 36 months
Other Overall survival (OS) The duration of overall survival (OS) will be measured from the time of first study drug administration until the date of death. OS will be assessed using KAPLAN-MEIER methods. 36 months
Primary Incidence of Adverse Events (AE) Adverse Events will be summarized by MedDRA system organ class and preferred term. Separate tabulations will be produced for all treatment emergent AEs, treatment related AEs, Serious Adverse Events (SAEs), discontinuations due to AEs, and AEs of at least NCI CTCAE grade 3 severity. 36 months
Primary Dose Limiting Toxicity of PY159 (Part A only) Evaluation of dose-limiting toxicity (DLT). 21 days
Secondary Measure PY159 concentration at the end of infusion (CEOI) Measure PY159 concentration at the end of infusion (CEOI) after the first dose. 36 months
Secondary Measure PY159 maximum concentration (Cmax) Measure PY159 maximum concentration (Cmax) at various time points during Cycle 1. All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled pharmacokinetics (PK) time point after start of dosing. 36 months
Secondary Measure PY159 concentration at the trough level (Ctrough) Measure PY159 concentration at the trough level (Ctrough). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing. 36 months
Secondary Measure PY159 Area under the curve (AUC)0-t Measure PY159 Area under the curve (AUC)0-t. All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. 36 months
Secondary Measure PY159 half-life (T1/2) Measure PY159 half-life (T1/2). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. 36 months
Secondary Measure PY159 Clearance (CL) Measure PY159 Clearance (CL). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. 36 months
Secondary Measure PY159 Volume at Steady State (Vss) Measure PY159 Volume at Steady State (Vss). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. 36 months
Secondary Incidence of Anti-Drug Antibody (ADA) formation to PY159 To evaluate the incidence of anti-drug antibody (ADA) formation to PY159 36 months
Secondary Determining PY159 time to maximum concentration (Tmax) Determining PY159 time to maximum concentration (Tmax) during Cycle 1. 36 months
Secondary Objective response rate (ORR) The incidents of ORR is defined as either a complete or partial response (PR) per RECIST. Subjects with no baseline data will be considered no responders. ORR will be summarized by dose, tumor type, and overall. ORR will be summarized descriptively. 36 months
Secondary Clinical Benefit Rate (CBR) Defined as the percentage of subjects who have achieved complete response (CR), partial response (PR) and stable disease (SD). 36 months
Secondary Duration of response (DOR) DOR will be calculated to determine durability. DOR will be measured from the time by which the criteria for CR or PR-whichever is recorded first-are met until the first date by which recurrent or progressive disease is objectively documented. DOR will be assessed using KAPLAN-MEIER methods. 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2